Replimune Group (NASDAQ:REPL) Trading 11.1% Higher – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) traded up 11.1% during trading on Friday . The company traded as high as $8.03 and last traded at $7.82. 1,484,366 shares changed hands during mid-day trading, an increase of 13% from the average session volume of 1,316,213 shares. The stock had previously closed at $7.04.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wedbush raised their target price on Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Piper Sandler lifted their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Replimune Group Trading Up 12.6%

The business has a 50 day simple moving average of $7.93 and a 200-day simple moving average of $7.55. The stock has a market capitalization of $654.78 million, a price-to-earnings ratio of -2.31 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares in the last quarter. Millennium Management LLC raised its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after buying an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares in the last quarter. AlphaQuest LLC lifted its stake in Replimune Group by 99.9% in the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock valued at $92,000 after acquiring an additional 4,925 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Replimune Group during the 2nd quarter worth approximately $403,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.